EUPRAXIA PHARMACEUTICALS INC (EPRX) Fundamental Analysis & Valuation

NASDAQ:EPRX • CA29842P1053

Current stock price

7.51 USD
-0.07 (-0.92%)
At close:
7.51 USD
0 (0%)
After Hours:

This EPRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. EPRX Profitability Analysis

1.1 Basic Checks

  • EPRX had negative earnings in the past year.
  • EPRX had a negative operating cash flow in the past year.
  • In the past 5 years EPRX always reported negative net income.
  • In the past 5 years EPRX always reported negative operating cash flow.
EPRX Yearly Net Income VS EBIT VS OCF VS FCFEPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of EPRX (-31.81%) is better than 64.09% of its industry peers.
  • With a decent Return On Equity value of -32.63%, EPRX is doing good in the industry, outperforming 72.78% of the companies in the same industry.
Industry RankSector Rank
ROA -31.81%
ROE -32.63%
ROIC N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EPRX Yearly ROA, ROE, ROICEPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

  • EPRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPRX Yearly Profit, Operating, Gross MarginsEPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. EPRX Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for EPRX has been increased compared to 1 year ago.
  • EPRX has more shares outstanding than it did 5 years ago.
  • EPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EPRX Yearly Shares OutstandingEPRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EPRX Yearly Total Debt VS Total AssetsEPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • An Altman-Z score of 114.54 indicates that EPRX is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of EPRX (114.54) is better than 98.84% of its industry peers.
  • EPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 114.54
ROIC/WACCN/A
WACCN/A
EPRX Yearly LT Debt VS Equity VS FCFEPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 23.98 indicates that EPRX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 23.98, EPRX belongs to the best of the industry, outperforming 97.10% of the companies in the same industry.
  • EPRX has a Quick Ratio of 23.98. This indicates that EPRX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 23.98, EPRX belongs to the top of the industry, outperforming 97.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 23.98
Quick Ratio 23.98
EPRX Yearly Current Assets VS Current LiabilitesEPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. EPRX Growth Analysis

3.1 Past

  • The earnings per share for EPRX have decreased by -6.65% in the last year.
EPS 1Y (TTM)-6.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, EPRX will show a small growth in Earnings Per Share. The EPS will grow by 7.42% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.82%
EPS Next 2Y9.59%
EPS Next 3Y16.64%
EPS Next 5Y7.42%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPRX Yearly Revenue VS EstimatesEPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
EPRX Yearly EPS VS EstimatesEPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. EPRX Valuation Analysis

4.1 Price/Earnings Ratio

  • EPRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EPRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPRX Price Earnings VS Forward Price EarningsEPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPRX Per share dataEPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as EPRX's earnings are expected to grow with 16.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.59%
EPS Next 3Y16.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EPRX Dividend Analysis

5.1 Amount

  • EPRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EPRX Fundamentals: All Metrics, Ratios and Statistics

EUPRAXIA PHARMACEUTICALS INC

NASDAQ:EPRX (3/18/2026, 8:03:48 PM)

After market: 7.51 0 (0%)

7.51

-0.07 (-0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-31
Inst Owners31.44%
Inst Owner ChangeN/A
Ins Owners15.89%
Ins Owner ChangeN/A
Market Cap447.22M
Revenue(TTM)N/A
Net Income(TTM)-29.37M
Analysts82.22
Price Target10.82 (44.07%)
Short Float %3.95%
Short Ratio9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.08%
Min EPS beat(2)-41.57%
Max EPS beat(2)-18.58%
EPS beat(4)0
Avg EPS beat(4)-41.02%
Min EPS beat(4)-80.04%
Max EPS beat(4)-18.58%
EPS beat(8)3
Avg EPS beat(8)-23.25%
EPS beat(12)7
Avg EPS beat(12)-9.73%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.71%
PT rev (3m)20.3%
EPS NQ rev (1m)-53.3%
EPS NQ rev (3m)-20.24%
EPS NY rev (1m)-44.87%
EPS NY rev (3m)6.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.97
P/tB 4.97
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0
BVpS1.51
TBVpS1.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.81%
ROE -32.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 214.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.98
Quick Ratio 23.98
Altman-Z 114.54
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.53%
Cap/Depr(5y)142.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.93%
EPS Next Y23.82%
EPS Next 2Y9.59%
EPS Next 3Y16.64%
EPS Next 5Y7.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.36%
EBIT Next 3Y-2.11%
EBIT Next 5Y16.98%
FCF growth 1Y-0.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.17%
OCF growth 3YN/A
OCF growth 5YN/A

EUPRAXIA PHARMACEUTICALS INC / EPRX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EUPRAXIA PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to EPRX.


What is the valuation status for EPRX stock?

ChartMill assigns a valuation rating of 0 / 10 to EUPRAXIA PHARMACEUTICALS INC (EPRX). This can be considered as Overvalued.


Can you provide the profitability details for EUPRAXIA PHARMACEUTICALS INC?

EUPRAXIA PHARMACEUTICALS INC (EPRX) has a profitability rating of 1 / 10.


What is the expected EPS growth for EUPRAXIA PHARMACEUTICALS INC (EPRX) stock?

The Earnings per Share (EPS) of EUPRAXIA PHARMACEUTICALS INC (EPRX) is expected to grow by 23.82% in the next year.